GenVec Inc. GNVC & Novartis AG NVS Ink Deal - Hearing Loss Treatment

January 19, 2010 - Shares of GenVec Inc. (GNVC) are surging this morning as the company has hooked up with Novartis AG (NVS) to work on a treatment for Hearing Loss and Balance disorders. GenVec Inc stock is trading at $2.08, Up 19.5% in pre market. Below is a small piece of the press release.


GenVec, Inc. (NASDAQ: GNVC) today announced that the company has entered into a research collaboration and license agreement. GenVec and Novartis will collaborate to discover and develop novel treatments for hearing loss and balance disorders. Preclinical results suggest that delivery of the atonal gene using GenVec’s innovative adenovector technology may have the potential to restore hearing and balance function.

Full Press Release



Today's Biggest Stock Market Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Stocks for 2010

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free